462 related articles for article (PubMed ID: 8707772)
1. The prostate specific antigen. Its use as a tumor marker for prostate cancer.
Kantoff PW; Talcott JA
Hematol Oncol Clin North Am; 1994 Jun; 8(3):555-72. PubMed ID: 8707772
[TBL] [Abstract][Full Text] [Related]
2. Rising prostate specific antigen after radical prostatectomy: a case based review.
Nasr R; Goldenberg SL
Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen in the diagnosis and staging of prostate cancer.
Jung P; Wolff JM; Mattelaer P; Jakse G
Acta Urol Belg; 1996 Sep; 64(3):1-6. PubMed ID: 8946774
[TBL] [Abstract][Full Text] [Related]
4. [Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate].
Chauvet B; Jacob T; Davin JL; Berger C; Vincent P; Reboul F
Bull Cancer Radiother; 1996; 83(4):334-44. PubMed ID: 9081335
[No Abstract] [Full Text] [Related]
5. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
6. A guideline to clinical utility of prostate specific antigen.
Farhat WA; Habbal AA; Khauli RB
Saudi Med J; 2000 Mar; 21(3):223-7. PubMed ID: 11533789
[TBL] [Abstract][Full Text] [Related]
7. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
8. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
Kamoi K; Babaian RJ
Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
[TBL] [Abstract][Full Text] [Related]
9. [Prostate-specific antigen: the most useful marker for prostate cancer].
Janssen T; Schulman C
Rev Med Brux; 1993; 14(9-10):279-83. PubMed ID: 7508631
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
Adolfsson J
Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
[TBL] [Abstract][Full Text] [Related]
11. Is prostate-specific antigen still the best tumor marker for prostate cancer?
Leewansangtong S; Soontrapa S; Tantiwong A
J Med Assoc Thai; 1999 Oct; 82(10):1034-40. PubMed ID: 10561969
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
13. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
Okubo Y; Ito T
Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
[TBL] [Abstract][Full Text] [Related]
14. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
15. [Use of prostate specific antigen. A review].
Brasso K; Skaarup P; Roosen JU; Iverson P
Ugeskr Laeger; 1998 Jul; 160(31):4510-6. PubMed ID: 9700305
[TBL] [Abstract][Full Text] [Related]
16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and treatment of localized prostate cancer].
Usami M; Arai Y
Hinyokika Kiyo; 1996 Oct; 42(10):759-61. PubMed ID: 8951471
[TBL] [Abstract][Full Text] [Related]
18. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
[TBL] [Abstract][Full Text] [Related]
19. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
20. [Clinical surveillance after surgery for prostate cancer].
Guercio S; Terrone C; Scarpa RM
Recenti Prog Med; 2003 Mar; 94(3):110-3. PubMed ID: 12677777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
